Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28

US11912769B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Xavier Valencia · Bethesda, US
• John P. Throup · New Hope, US
• Steven G. Nadler · Princeton, US
• Suzanne J. Suchard · Wilmington, US
• Dominique Duchesne · Yardley, US
• Xiaoni Liu · Yardley, US
• Rong Shi · Princeton, US
• Diane E. Shevell · Westfield, US
• Jenny H. Xie · Princeton, US
• Marek Honczarenko · Princeton, US

Key dates

• Filing date: Jan 25, 2022
• Grant date: Feb 27, 2024
• Expiry date: Jan 25, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.